Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies - Contacts and Locations

Home

Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

This study has been suspended.

Study NCT00070239. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00070239

Locations


United States, Massachusetts
	Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
	Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Dana-Farber Cancer Institute

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Geoffrey Shapiro, MD, PhD	Dana-Farber Cancer Institute